1. Clinical Value of Serum Cytokeratin 19 Fragment and Sialyl-Lewis X in Non-Small Cell Lung Cancer 
Shinjiro Mizuguchi, MD, PhD, Noritoshi Nishiyama, MD, PhD, Takashi Iwata, MD, PhD, Tatsuya Nishida, MD, PhD, Nobuhiro Izumi, MD, PhD, Takuma Tsukioka, MD, Kiyotoshi Inoue, MD, PhD, Masao Kameyama, MD, PhD, Shigefumi Suehiro, MD, PhD 
The Annals of Thoracic Surgery 
Volume 83, Issue 1, Pages (January 2007)
DOI: /j.athoracsur
Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Survival rates of patients with non-small cell lung cancer, based on the combination of serum sialyl-Lewis x and cytokeratin 19 fragment. (…. = both negative [n = 97]; — = either positive (n = 136); ■■■ = both positive (n = 39); SD = significantly different.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
Survival rates of patients with non-small cell lung cancer, based on histologic stage. (…. = histologic stage I (n = 140); — = histologic stage II (n = 45); ■■■ = histologic stage III/IV (n = 87); SD = significantly different.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

4. Fig 3
Survival rates of patients with NSCLC, based on the clinical stage. (…. = clinical stage I (n = 186); — = clinical stage II (n = 48); ■■■ = clinical stage III/IV (n = 38); NS = not significantly different.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions